Exploring spinal degenerative diseases therapy targets through druggability genes: a Mendelian randomization study

Area of Science:

• Genetics and Precision Medicine
• Orthopedics and Spine Surgery
• Pharmacology and Drug Discovery

Background:

• Spinal degenerative diseases (SDDs) present a growing global health challenge, increasing patient morbidity and healthcare costs.
• Identifying genetic factors and therapeutic targets is crucial for effective SDD management.
• Mendelian randomization (MR) offers a robust approach to investigate causal relationships between genetic variants and disease risk.

Purpose of the Study:

• To identify novel genetic therapeutic targets for managing spinal degenerative diseases (SDDs) through Mendelian randomization.
• To investigate the causal associations between specific genes and the risk of osteoporosis (OP), spinal canal stenosis (SCS), and prolapsed disc/slipped disc (PD/SD).
• To assess the druggability of identified targets for potential therapeutic applications.

Main Methods:

• Two-sample Mendelian randomization (TSMR) analyses were performed to assess gene-disease causal relationships.
• Summary data-based Mendelian randomization (SMR) analyses were utilized to strengthen findings.
• Bayesian co-localization and druggability assessments were employed to validate and evaluate potential therapeutic targets.

Main Results:

• The study identified several genes causally associated with SDD risk.
• ESR1 was found to be positively associated with an increased risk of osteoporosis (OP).
• HTT was associated with a reduced risk of spinal canal stenosis (SCS), while PIK3C2A was linked to an increased risk of SCS.

Conclusions:

• This research highlights potential genetic targets, including ESR1, HTT, and PIK3C2A, for the management of SDDs.
• The findings provide a foundation for developing novel therapeutic strategies targeting these genes.
• The study contributes valuable insights into the genetic underpinnings of SDDs and their potential pharmacological interventions.